Online

ONLINE:

Cell & Gene Therapy Strategy Meeting

Following fantastic feedback we’re thrilled to announce we will be running another Online Cell & Gene Therapy Strategy Meeting. Discuss with your peers and forge new connections from the comfort of your own home

Dates

20 Oct, 2020

Online Strategy Meetings

Cell & Gene Therapy insights without ever leaving your home

Need a unique online conference experience? Looking for a chance for real discussions and genuine networking? Proventa International’s online manufacturing strategy meetings can help you make those important connections through interactive roundtable discussions, exclusive networking apps and keynote panel debates – all in a totally online format. Join cell and gene therapy professionals from all over the world. Engage with your senior peers, discover new insights and help take your company to the next level.

See the Full Agenda and Speaker List

Online Strategy Meetings

What makes our online strategy meetings unique?

No other event creates such a unique and personalised online experience – tailored agenda and senior delegation, our online strategy meetings provide the perfect learning and networking environment.

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Global Networking

With senior delegation from big pharma and innovative biotech from all over the globe, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at roundtable discussions and ensure your whole day delivers the insights you need to hear.

Totally Online Format

It’s more important than ever to encourage collaboration while promoting safety and accessibility. And that’s exactly what you can expect from our online meeting format.

Meet some of the October 2020 Facilitators

André Gerber

Professor of RNA Biology, Director Core Research Facilities University of Surrey

Geert Mudde

Founder and CSO OncoQR ML

Session – Targeted immunotherapy does not mean tumour specific immunotherapy. How can we do better than that?
Dr. Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992 he joined the pharmaceutical/biotech industry, where he held several senior management positions at the Novartis Research Institute in Vienna, Austria, the Parke Davis Research Institute in Fresnes, France, Ingenium Pharmaceuticals, Martinsried, Germany, and at igeneon AG, Vienna, Austria. Finally, in 2006, while joining Baxter BioScience in Vienna as interim manager, Dr. Mudde co-founded the biotech company f-star Biotechnology, where he served as “Chief Scientific Officer” from 2007 to 2009. In 2009, together with Christof Langer, he started to develop the S-TIR™ technology platform for human specific therapeutic vaccines which led to the foundation of S-TARget therapeutics GmbH in 2010. Since then he serves as CSO and managing director for S-TARget therapeutics as well as for the S-TIR™ technology spin-off companies OncoQR ML GmbH and TYG oncology Ltd., which were both founded in 2013

Dr. Antoine Heron

Head of Cell Therapy Process Innovation Merck KGaA

Khalid Shah

Vice Chair of Research, Director Center for Stem Cell Therapeutics and Imaging , Associate Professor Harvard Medial School

Session – Cell based therapies for Cancer: Journey from Innovation to Translation
Dr. Khalid Shah is the Vice Chair of Research at Brigham and Women’s Hospital (BWH) in Boston, MA. He is also the Director of the Center for Stem Cell Therapeutics and Imaging and a Principal Faculty at Harvard Stem Cell Institute in Boston.
In recent years, Dr. Shah and his team have pioneered major developments in the cancer research field, successfully developing therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, JNCI, Stem Cells, Lancet Oncology and Nature Reviews Cancer. The potential of developing novel cancer therapies in his laboratory has been recognized by many cancer alliances and associations. Based on this, he has received the young investigator award from ACGT, Research fellow award from ACS, Innovation awards from James McDonnell Foundation, ABTA, Goldhirsh Foundation and American Association of Radiology. Recently, Dr. Shah’s work has been highlighted in the media world-wide including features on BBC and CNN. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of stem cell therapy and oncology. The technologies from Dr. Shah’s laboratory have led to the foundation of a biotech company, AMASA Technologies Inc. whose main objective is the clinical translation of therapeutic stem cells in cancer patients.
Dr. Shah has participated in the training of numerous undergraduate, graduate students and residents at MGH and the potential of his mentoring has been recognized by Harvard Medical School, who awarded him the Harvard Young Mentor Award. Dr. Shah has also launched an outreach program to create public awareness of the fervent need for effective cancer treatments, and the current research on the cusp of clinical translation that would yield paramount progress for cancer patients.

Eric Halioua

Chief Executive Officer & President PDC*Line Pharma

Serial entrepreneur that combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. During his career he achieved together with its different teams to bring four drug candidates from research to the clinics (up to phase IIb). Overall, he has raised as of now a total of more than €160 million from VCs and strategic partners in Europe, USA, Japan and Korea and have had numerous successes in the sale and initial public offering of biotechnology companies. He is President and CEO of the biotechnology company PDC-Line Pharma and board member of Cell Matters. He was also a Board Member of the French biotechnology company Vivalis/Valneva and the Belgian company Bioxodes, the Health Cluster of Wallonia BIOWIN and the industrial association European Biotechnology Entreprises (EBE).
Eric have been as well co-Inventor of the first worldwide GMP approved mobile manufacturing unit for cell therapy (WO 2014049151 A). He worked for 12 years as a Principal in the Healthcare and Life Sciences Practice of Arthur D. Little where he led work in the areas of strategy, M&A and technology & innovation management.
He is co-founder of 4 biotechnology companies called Myosix, Murigenetics, Digital-Orthopaedics and HairClone.
-Myosix is a tissue engineering company specialising in musculoskeletal cells culture used in the regeneration of the heart muscle. The company has been bought by Genzyme mid-2002. 
-Murigenetics is a Biotechnology company developing therapies for genetic disorders. 
-Digital Orthopaedics is a Digital Health company providing access to a comprehensive Clinical Decision Support System for musculoskeletal pathologies. 
-HairClone is a Biotechnology company developing cell-based hair treatments and Follicle Banking Service.
Eric worked for IsoHealthcare Group (eventually acquired by the Monitor Group) as a Senior Consultant where I focused on leading healthcare and life sciences issues. He also worked as a strategic marketing Manager for the “Centre Européen de Bioprospective” and as project leader in the corporate R&D centre of Zeneca in UK.
Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.

Michael Zaiac

Head of Medical Affairs Oncology Region Europe Novartis

Valeria Frigerio-Regazzoni

Global Compliance Head of Quality Auditing & Consulting Group Merck Group

Dirk Boehm

Site Head/VP, Global Biologics Manufacturing, Quality, Strategy Bayer

Sabine Chlosta

Chief Medical Officer Triumvira Immunologics

Reasons to Attend the Virtual Strategy Meeting

Fully Interactive Virtual Conference

We’re all bored of the same webinar format by now. Instead, join intimate groups of like-minded professionals and discuss the topics that really matter to you

Personalised and Easy to Join Agenda

Pick the roundtable discussions that you want to be part of. Simply choose your sessions and we will send you the direct links and calendar reminder to join

Senior Decision Makers

All our roundtable discussions are aimed at director level and above. Discover how your peers are tackling the industries biggest challenges and have your thoughts heard

Private and Intimate Discussions

Each sessions is read by an industry expert and the roundtables are limited to ensure you have fruitful and genuine conversations with your colleagues

Agenda

CELL AND GENE THERAPY VECTORS (i.e. AAV & LENTIVECTORS) – RNA Therapeutic Approaches

CAR-T, TCR & T CELL IMMUNOTHERAPIES – Will We Ever Reach the Goal of an Allogeneic Off-the-Shelf T-Cell Therapy or Should We Be Driving Optimisation of Autologous T-Cell Therapies?

CELL & GENE GMP MANUFACTURING – Reducing the High Manufacturing Cost of T-Cell Immunotherapies

CLINICAL RESEARCH – Evolving Trial Design to Meet the Needs of the Cell and Gene Therapy Space

SUPPLY CHAIN – International Shipping Logistics Strategies and Addressing Regulations Associated for Cell and Gene Supply Chains

STEM CELLS – Correcting Gene Defects Which Cause Functional Deficiencies When Producing Mature Cells from iPSCs

CELL AND GENE THERAPY VECTORS (i.e. AAV & LENTIVECTORS) – Addressing Dosing and Immune Response Issues in Gene Therapy Vectors

CAR-T, TCR & T CELL IMMUNOTHERAPIES – Optimising Autologous T-Cell Therapies – Reducing Vein-to-Vein Time and Cost

CELL & GENE GMP MANUFACTURING – Overcoming Problems Associated with Transitioning Manufacturing from Early-Phase to Late-Phase Development

CLINICAL RESEARCH – Increasing Patient Reach Whilst Maintaining Retention for Trials Which Require Frequent Site Visits

SUPPLY CHAIN – Learning from COVID-19 and
Optimising the Supply Chain to be “Global Disruption-Proof”

STEM CELLS – Improving Manufacturing Potential
and Efficacy of Stem Cells to Match the Therapeutic Potential

CELL AND GENE THERAPY VECTORS (i.e. AAV & LENTIVECTORS) – Overcoming Challenges in Obtaining a High-Quality Sustainable Vector Supply

CAR-T, TCR & T CELL IMMUNOTHERAPIES – Leveraging High-Dimensional Multi-Omics Technologies for Comprehensive Profiling of CAR-T
Cells to Resolve Drug-Product Complexity

CELL & GENE GMP MANUFACTURING – Overcoming Problems Associated with Transitioning Manufacturing from Early-Phase to Late-Phase Development

CLINICAL RESEARCH – Overcoming Challenges Associated with Scaling-Up to Late-Phase Clinical Trials for Autologous Therapies

SUPPLY CHAIN – Remote Audits & Inspections: the
new future?

STEM CELLS – Addressing the Need for Better, More Accurate Stem Cell Biomarkers

Quick Links

Want to find out more?

Get help registering

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

Manufacturing

ONLINE:

Cell & Gene Therapy Strategy Meeting

Dates

Cell & Gene Therapy insights without ever leaving your home

What makes our online strategy meetings unique?

Roundtable Discussions

Global Networking

Personalised Agenda

Totally Online Format

Meet some of the October 2020 Facilitators

André Gerber

Geert Mudde

Dr. Antoine Heron

Khalid Shah

Eric Halioua

Michael Zaiac

Valeria Frigerio-Regazzoni

Dirk Boehm

Sabine Chlosta

Reasons to Attend the Virtual Strategy Meeting

Fully Interactive Virtual Conference

Personalised and Easy to Join Agenda

Senior Decision Makers

Private and Intimate Discussions

Agenda

Keynote Presentation

Break

Roundtable One

Break

Roundtable Two

Break

Keynote Presentation

Break

Roundtable Three

Pro-Partners

Talent Acquisition Sponsor

Want to find out more?

Select days you wish to attend You can add multiple days

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Urology

Gastroenterology

Oncology

Vaccines

Haematology

Ophthalmology

Thrombosis